Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 4/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13717001 | 1.00 | BCHE (0.38) | BCHECES1RXRAHDAC3HDAC4 | |
| SCHEMBL4711216 | 0.79 | PRKDC (0.38) | RXRAALDH1A1HPGDPOLBL3MBTL1 | |
| SCHEMBL21238596 | 0.75 | BCHE (0.37) | BCHECES1RXRAHDAC3HDAC4 | |
| SCHEMBL3170254 | 0.75 | RXRA (0.44) | RXRAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13716890 | 0.75 | PGR (0.40) | KDM4EALDH1A1HPGDMEN1PGR | |
| SCHEMBL6455621 | 0.75 | PGR (0.40) | KDM4EALDH1A1HPGDMEN1PGR | |
| SCHEMBL4712549 | 0.74 | NPC1 (0.32) | — | |
| SCHEMBL9860146 | 0.74 | CMA1 (0.40) | KDM4EALDH1A1HPGDKMT2ABACE1 | |
| SCHEMBL9860639 | 0.74 | CMA1 (0.40) | KDM4EALDH1A1HPGDKMT2ABACE1 | |
| SCHEMBL23753555 | 0.71 | GRIN2D (0.34) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391093-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2910549-A1 | 1,2,3,4-TETRAHYDRO-1,1,4,4-TETRAMETHYLNAPHTHALENE DERIVATIVES USEFUL AS RXR MODULATORS FOR TREATING ALZHEIMER'S DISEASE AND CANCER | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910549-A1 | 1,2,3,4-TETRAHYDRO-1,1,4,4-TETRAMETHYLNAPHTHALENE DERIVATIVES USEFUL AS RXR MODULATORS FOR TREATING ALZHEIMER'S DISEASE AND CANCER | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| EP-2755942-A2 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013040227-A2 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391093-B2 | Therapeutic compounds | PSEN1, PSEN2, MAPT | BCHE 19/4885CES1 2286/4885RXRA 3433/4885 |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | PSEN1, PSEN2, MAPT | BCHE 19/4885CES1 2286/4885RXRA 3433/4885 |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | HSD17B10, IDH2, INSR | BCHE 3556/4885CES1 238/4885RXRA 1054/4885 |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | MAPT, PSEN1, PSEN2 | BCHE 17/4885CES1 2562/4885RXRA 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.